





Optimising patient outcomes with 1L lorlatinib treatment in ALK+ aNSCLC^V

Save the date

Webinar with live Q&A session Monday, 16 June 2025 at 18:00 and 23:00

Click Here or Scan the **QR Code to Register**



Dear Doctor.

We invite you to a 60-minute webinar titled 'Optimising patient outcomes with 1L Iorlatinib treatment in ALK+ aNSCLC' on Monday, 16 June 2025 at 18:00 and 23:00.

The webinar will cover data from the 5-year follow-up of the CROWN trial, including systemic and intracranial efficacy, safety, and dose modification of 1L lorlatinib. We will discuss patient-centric approaches to managing lorlatinib-associated AEs through case studies, highlighting the importance of patient engagement and support networks. There will also be a live Q&A session.



Dr Maximilian Hochmair (Austria)



Dr Christine Lovly (USA)

Agenda

Session title	Presenter
Welcome and introductions	Dr Maximilian Hochmair
Lorlatinib in ALK+ aNSCLC: 5-year update from CROWN	Dr Maximilian Hochmair
A patient-centric approach to managing Iorlatinib AEs pragmatically	Dr Christine Lovly
Case Study 1: Optimising the management of CNS effects	Dr Maximilian Hochmair
Case Study 2: Optimising the management of weight gain and oedema	Dr Christine Lovly
Q&A	Both speakers

We look forward to welcoming you to what promises to be an interesting and engaging event.

Dr Maximilian Hochmair and Dr Christine Lovly

Scan here for full Prescribing Information.

PP-LOR-MYS-0190-28APR2025

LORVIQUA® (Lorlatinib) Malaysia Prescribing Information Accessed on

Available at: https://labeling.pfizer.com/ShowLabeling.aspx?id=17716

For Healthcare Professionals Only.

3 June 2024

1L, first-line; AE, adverse event; ALK, anaplastic lymphoma kinase; aNSCLC, advanced non-small cell lung cancer; CNS, central nervous system; Q&A, question and answer





